Expression of cMyBP-C in hiPSC-CMs in monolayer culture and hiPSC-ECT. (A and F) Western blot analysis of cMyBP-C, α-actinin (ACTN), and GAPDH in day 30 hiPSC-CM (A) and hiPSC-ECT (F). The center and right-hand panels in A and F show cMyBP-C protein levels normalized to ACTN and GAPDH, respectively, cMyBP-C+/+, cMyBP-C+/−, and cMyBP-C−/− in day 30 hiPSC-CM (A) and hiPSC-ECT (F). (B–E, and G–J) Box and whisker plot of qRT-PCR assessment of MYBPC3 transcript levels in cMyBP-C+/+, cMyBP-C+/−, and cMyBP-C−/− day 30 hiPSC-CM (B) and hiPSC-ECT (G). Immunocytochemistry preformed on day 30 hiPSC-CM (C–E) and immunohistochemistry performed on hiPSC-ECT (H–J) showing cMyBP-C (green), α-actinin (red), and DAPI (blue) in cMyBP-C+/+ (C and H), cMyBP-C+/− (D and I), and cMyBP-C−/− (E and J). n ≥ 6 biological replicates; *P < 0.05; **P < 0.01; ***P < 0.001 as calculated by one-way ANOVA with Tukey’s multiple comparisons test; see Table S3 for specific P values.
Figure 1.

Expression of cMyBP-C in hiPSC-CMs in monolayer culture and hiPSC-ECT. (A and F) Western blot analysis of cMyBP-C, α-actinin (ACTN), and GAPDH in day 30 hiPSC-CM (A) and hiPSC-ECT (F). The center and right-hand panels in A and F show cMyBP-C protein levels normalized to ACTN and GAPDH, respectively, cMyBP-C+/+, cMyBP-C+/−, and cMyBP-C−/− in day 30 hiPSC-CM (A) and hiPSC-ECT (F). (B–E, and G–J) Box and whisker plot of qRT-PCR assessment of MYBPC3 transcript levels in cMyBP-C+/+, cMyBP-C+/−, and cMyBP-C−/− day 30 hiPSC-CM (B) and hiPSC-ECT (G). Immunocytochemistry preformed on day 30 hiPSC-CM (C–E) and immunohistochemistry performed on hiPSC-ECT (H–J) showing cMyBP-C (green), α-actinin (red), and DAPI (blue) in cMyBP-C+/+ (C and H), cMyBP-C+/− (D and I), and cMyBP-C−/− (E and J). n ≥ 6 biological replicates; *P < 0.05; **P < 0.01; ***P < 0.001 as calculated by one-way ANOVA with Tukey’s multiple comparisons test; see Table S3 for specific P values.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal